Morris Birnbaum joins Pfizer as Chief Scientific Officer, Cardiovascular and Metabolic Disease Research

US pharma giant Pfizer has announced that Morris Birnbaum has joined the company as Chief Scientific Officer for Cardiovascular and Metabolic Disease Research. Dr Birnbaum (pictured) will report directly to Rod MacKenzie, Group Senior Vice President and Head of PharmaTherapeutics Research & Development.

“As the new leader of our Cardiovascular and Metabolic Disease Research Unit, Dr Birnbaum brings significant scientific expertise that will help us continue the progress of clinical programs in areas of need such as type 2 diabetes, diabetic nephropathy, and hyperlipidemia,” said Dr MacKenzie. “He is among the leading contributors to our contemporary understanding of the regulation of intracellular metabolism, and an excellent addition to our team. His scientific credentials and knowledge will help Pfizer pursue our goals to achieve industry leadership from the strong position that we currently hold, and to deliver unique therapies for patients.”